Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Nuo Luo"'
Autor:
Naifu Nie, Haodong Zhou, Kejun Zhang, Lan liu, Nuo Luo, Renyuan Wang, Xin Li, Mengxiao Zhu, Chen Hu, Yubo Wang, Zhulin Liu, Li Li, Yong He
Publikováno v:
Thoracic Cancer, Vol 13, Iss 18, Pp 2574-2583 (2022)
Abstract Background The prognosis of non–small‐cell lung cancer (NSCLC) with leptomeningeal metastasis (LM) is poor. Detection of cell‐free DNA (cfDNA) by next generation sequencing (NGS) in cerebrospinal fluid (CSF) may facilitate diagnosis of
Externí odkaz:
https://doaj.org/article/9f38c3c1e4904f3c97d0cc4f42ee0580
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Long-term survival benefit has been noticed in non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), such as PD-1 inhibitors. However, it is still controversial whether patients with EGFR-activating mutations m
Externí odkaz:
https://doaj.org/article/d10ac4d819fa445395095b0de263acf9
Publikováno v:
Cancer Medicine, Vol 8, Iss 18, Pp 7669-7678 (2019)
Abstract Background Immune‐therapy with anti‐PD1 inhibitors, such as pembrolizumab, is revolutionizing the treatment of non‐small cell lung cancers (NSCLC). However, identifying patients for the potential therapeutic response and predicting the
Externí odkaz:
https://doaj.org/article/923cf3b6254b49bc8ec1657d4e0c64c9
Autor:
Chen Hu, Qiang Ma, Nengsheng Li, Nuo Luo, Shuai Hao, Minrui Jiang, Fei Pang, Yan Yang, Li Li, Yong He
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Immune checkpoint inhibitors have brought long-term survival benefit in advanced non-small cell lung cancer patients without driver gene mutations. Even after withdrawal of immunotherapy for a maximum of two years, some patients still benefit from th
Externí odkaz:
https://doaj.org/article/6114d3a85aa942f99f9ed5812156c25a
Autor:
Jie Tian, Hongdan Wang, Conghua Lu, Lan Liu, Xianquan Zhang, Yunbo Xie, Rutian Li, Xin Lv, Dan Fu, Ling Zhang, Xisheng Fang, Xuming Wang, Jing Hu, Xinyi Liu, Xiaochun Huang, Qian Zhao, Nuo Luo, Huan Tang, Zhaoyang Zhong, Yong He, Li Li
Publikováno v:
Lung Cancer. 181:107255
Publikováno v:
Annals of Palliative Medicine. 10:8413-8419
Although tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have a favorable and durable treatment response, almost all patients will eventually acquire resistance and develop disease progression. Re-administration of
Publikováno v:
Annals of Palliative Medicine. 10:210-219
Background Immune checkpoint inhibitors (ICIs) have become the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). However, the safety and efficacy of ICIs in severe advanced NSCLC patients with poor performance status (
Publikováno v:
Science of The Total Environment. 856:159083
The development of bifunctional catalysts is an effective way to simultaneously address the slow kinetics of oxygen reduction reaction (ORR) on the cathode and biofilm contamination in the microbial fuel cells (MFC). Cu-N/C@Cu composites were synthes
Autor:
Yong He, Yan Yang, Nuo Luo, Li Li, Chen Hu, Minrui Jiang, Shuai Hao, Nengsheng Li, Qiang Ma, Fei Pang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Immune checkpoint inhibitors have brought long-term survival benefit in advanced non-small cell lung cancer patients without driver gene mutations. Even after withdrawal of immunotherapy for a maximum of two years, some patients still benefit from th
Autor:
Yinghui Zheng, Yawen Gu, Li Han, Minmin Zhang, Yu Zhang, Ning Gu, Lin Liu, Nuo Luo, Zhengcao Liu, Shukui Qin
Background We previously found that (via inhibition of the VEGF/VEGFR signaling pathway) ckgroundSevacizumab (Sev), an anti-VEGF monoclonal antibody, was proven to have a superior inhibitory effect than bevacizumab (Bev) on the growth of hepatocellul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::504368bfc1f68b7d0bb1a4de3473cec7
https://doi.org/10.21203/rs.3.rs-704885/v1
https://doi.org/10.21203/rs.3.rs-704885/v1